Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946931 | 0.93 | PTGES (0.48) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL14946972 | 0.88 | KMT2A (0.46) | TAS2R14PTGESTAS2R8CXCR3LMNA | |
| SCHEMBL14950180 | 0.81 | MAPT (0.48) | POLBTP53 | |
| SCHEMBL14950184 | 0.81 | MAPT (0.48) | POLBLMNATP53 | |
| SCHEMBL14950259 | 0.81 | PTGS2 (0.45) | — | |
| SCHEMBL14950288 | 0.80 | MAPT (0.43) | POLBLMNATP53 | |
| SCHEMBL14946903 | 0.77 | PTGS2 (0.42) | — | |
| SCHEMBL14938309 | 0.76 | CNR2 (0.47) | CNR2TAS2R14CNR1LMNATP53 | |
| SCHEMBL14946884 | 0.75 | MCL1 (0.52) | POLB | |
| SCHEMBL525596 | 0.74 | FAAH (0.47) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | CNR2 483/4885TAS2R14 1525/4885POLB 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.